Literature DB >> 26802049

Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.

Chi Keung Cheng1, Natalie P H Chan1, Thomas S K Wan1, Lai Ying Lam1, Coty H Y Cheung1, Terry H Y Wong1, Rosalina K L Ip1, Raymond S M Wong2, Margaret H L Ng3.   

Abstract

Helicase-like transcription factor is a SWI/SNF chromatin remodeling factor involved in various biological processes. However, little is known about its role in hematopoiesis. In this study, we measured helicase-like transcription factor mRNA expression in the bone marrow of 204 adult patients with de novo acute myeloid leukemia. Patients were dichotomized into low and high expression groups at the median level for clinicopathological correlations. Helicase-like transcription factor levels were dramatically reduced in the low expression patient group compared to those in the normal controls (n=40) (P<0.0001). Low helicase-like transcription factor expression correlated positively with French-American-British M4/M5 subtypes (P<0.0001) and complex cytogenetic abnormalities (P=0.02 for ≥3 abnormalities;P=0.004 for ≥5 abnormalities) but negatively with CEBPA double mutations (P=0.012). Also, low expression correlated with poorer overall (P=0.005) and event-free (P=0.006) survival in the intermediate-risk cytogenetic subgroup. Consistent with the more aggressive disease associated with low expression, helicase-like transcription factor knockdown in leukemic cells promoted proliferation and chromosomal instability that was accompanied by downregulation of mitotic regulators and impaired DNA damage response. The significance of helicase-like transcription factor in genome maintenance was further indicated by its markedly elevated expression in normal human CD34(+)hematopoietic stem cells. We further demonstrated that helicase-like transcription factor was a RUNX1 target and transcriptionally repressed by RUNX1-ETO and site-specific DNA methylation through a duplicated RUNX1 binding site in its promoter. Taken together, our findings provide new mechanistic insights on genomic instability linked to helicase-like transcription factor deregulation, and strongly suggest a tumor suppressor function of the SWI/SNF protein in acute myeloid leukemia. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26802049      PMCID: PMC5004395          DOI: 10.3324/haematol.2015.137125

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  50 in total

1.  Brg1, the ATPase subunit of the SWI/SNF chromatin remodeling complex, is required for myeloid differentiation to granulocytes.

Authors:  Diana Vradii; Stefan Wagner; Diem N Doan; Jeffrey A Nickerson; Martin Montecino; Jane B Lian; Janet L Stein; Andre J van Wijnen; Anthony N Imbalzano; Gary S Stein
Journal:  J Cell Physiol       Date:  2006-01       Impact factor: 6.384

2.  The BAF53a subunit of SWI/SNF-like BAF complexes is essential for hemopoietic stem cell function.

Authors:  Veneta Krasteva; Manuel Buscarlet; Abigail Diaz-Tellez; Marie-Anne Bernard; Gerald R Crabtree; Julie A Lessard
Journal:  Blood       Date:  2012-09-26       Impact factor: 22.113

3.  Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.

Authors:  Bruno C Medeiros; Megan Othus; Min Fang; Frederick R Appelbaum; Harry P Erba
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

4.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Authors:  Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

5.  Functional interactions between Sp1 or Sp3 and the helicase-like transcription factor mediate basal expression from the human plasminogen activator inhibitor-1 gene.

Authors:  H Ding; A M Benotmane; G Suske; D Collen; A Belayew
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

6.  TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.

Authors:  Frank G Rücker; Richard F Schlenk; Lars Bullinger; Sabine Kayser; Veronica Teleanu; Helena Kett; Marianne Habdank; Carla-Maria Kugler; Karlheinz Holzmann; Verena I Gaidzik; Peter Paschka; Gerhard Held; Marie von Lilienfeld-Toal; Michael Lübbert; Stefan Fröhling; Thorsten Zenz; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Peter Lichter; Konstanze Döhner; Hartmut Döhner
Journal:  Blood       Date:  2011-12-20       Impact factor: 22.113

Review 7.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

8.  SHPRH and HLTF act in a damage-specific manner to coordinate different forms of postreplication repair and prevent mutagenesis.

Authors:  Jia-Ren Lin; Michelle K Zeman; Jia-Yun Chen; Muh-Ching Yee; Karlene A Cimprich
Journal:  Mol Cell       Date:  2011-03-10       Impact factor: 17.970

9.  Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer.

Authors:  Wai K Leung; Jun Yu; Alfa H C Bai; Michael W Y Chan; Ka-Kui Chan; Ka-Fai To; Francis K L Chan; Enders K W Ng; S C Sydney Chung; Joseph J Y Sung
Journal:  Mol Carcinog       Date:  2003-06       Impact factor: 4.784

10.  Integrative analysis of RUNX1 downstream pathways and target genes.

Authors:  Joëlle Michaud; Ken M Simpson; Robert Escher; Karine Buchet-Poyau; Tim Beissbarth; Catherine Carmichael; Matthew E Ritchie; Frédéric Schütz; Ping Cannon; Marjorie Liu; Xiaofeng Shen; Yoshiaki Ito; Wendy H Raskind; Marshall S Horwitz; Motomi Osato; David R Turner; Terence P Speed; Maria Kavallaris; Gordon K Smyth; Hamish S Scott
Journal:  BMC Genomics       Date:  2008-07-31       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.